INCB123667

DRUG6 trials

Sponsors

Incyte Corporation

Conditions

Healthy ParticipantsHepatic InsufficiencyLiver DiseasesOvarian CancerRenal Impairment

Phase 1

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

RecruitingNCT06909162

Incyte CorporationHealthy Participants

Start: 2025-05-05End: 2026-05-17Target: 51Updated: 2026-05-06

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

CompletedNCT07218744

Incyte CorporationHealthy Participants

Start: 2025-11-13End: 2025-12-10Updated: 2026-01-07

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Not yet recruitingNCT07559396

Incyte CorporationRenal Impairment

Start: 2026-05-15End: 2027-01-04Target: 16Updated: 2026-04-30

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Not yet recruitingNCT07559474

Incyte CorporationHepatic Insufficiency, Liver Diseases

Start: 2026-05-15End: 2027-04-13Target: 16Updated: 2026-04-30

Phase 2

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07023627

Incyte CorporationOvarian Cancer

Start: 2025-11-12End: 2027-10-24Target: 160Updated: 2026-05-08

Phase 3

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07214779

Incyte CorporationOvarian Cancer

Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-05-08